Regulation of Feto-Maternal Barrier by Matriptase- and PAR-2-Mediated Signaling Is Required for Placental Morphogenesis and Mouse Embryonic Survival

English version České info

Development of mammalian embryos is dependent on an efficient exchange of nutrients, oxygen, and waste products between the mother and the embryo. The interface between the two systems is provided by the placenta in a form of a specialized epithelium that both facilitates the transport of molecules between the mother and the embryo and screens the substances that can pass between the maternal and fetal tissues. We now show that two independent signaling pathways that include the serine proteases, matriptase and prostasin, and a G protein-coupled receptor PAR-2, are critical for the establishment of a functional feto-maternal interface by specifically regulating the barrier properties of the placental epithelium. Because aberrant formation of epithelial barriers is an underlying feature of a great variety of human developmental abnormalities, the identification of the two protease-dependent signaling pathways critical for the barrier formation in embryonic tissues may help pinpoint molecular mechanisms involved in the etiology of these conditions.

Vyšlo v časopise: Regulation of Feto-Maternal Barrier by Matriptase- and PAR-2-Mediated Signaling Is Required for Placental Morphogenesis and Mouse Embryonic Survival. PLoS Genet 10(7): e32767. doi:10.1371/journal.pgen.1004470
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1004470

Souhrn

Zdroje

1. RossantJ, CrossJC (2001) Placental development: lessons from mouse mutants. Nature reviews Genetics 2: 538–548.

2. WatsonED, CrossJC (2005) Development of structures and transport functions in the mouse placenta. Physiology 20: 180–193.

3. SandoviciI, HoelleK, AngioliniE, ConstanciaM (2012) Placental adaptations to the maternal-fetal environment: implications for fetal growth and developmental programming. Reproductive biomedicine online 25: 68–89.

4. PreslandRB, JurevicRJ (2002) Making sense of the epithelial barrier: what molecular biology and genetics tell us about the functions of oral mucosal and epidermal tissues. Journal of dental education 66: 564–574.

5. MarchiandoAM, GrahamWV, TurnerJR (2010) Epithelial barriers in homeostasis and disease. Annual review of pathology 5: 119–144.

6. GuillotC, LecuitT (2013) Mechanics of epithelial tissue homeostasis and morphogenesis. Science 340: 1185–1189.

7. LiuZ, ShiC, YangJ, ZhangP, MaY, et al. (2011) Molecular regulation of the intestinal epithelial barrier: implication in human diseases. Frontiers in bioscience 16: 2903–2909.

8. RobbinsJR, BakardjievAI (2012) Pathogens and the placental fortress. Current opinion in microbiology 15: 36–43.

9. BeerAE, SioJO (1982) Placenta as an immunological barrier. Biology of reproduction 26: 15–27.

10. Delorme-AxfordE, BayerA, SadovskyY, CoyneCB (2013) Autophagy as a mechanism of antiviral defense at the maternal-fetal interface. Autophagy 9: 2173–4.

11. RiquelmeG (2009) Placental chloride channels: a review. Placenta 30: 659–669.

12. StulcJ (1997) Placental transfer of inorganic ions and water. Physiological reviews 77: 805–836.

13. Basel-VanagaiteL, AttiaR, Ishida-YamamotoA, RainshteinL, Ben AmitaiD, et al. (2007) Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. American journal of human genetics 80: 467–477.

14. AlefT, TorresS, HausserI, MetzeD, TursenU, et al. (2009) Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. The Journal of investigative dermatology 129: 862–869.

15. SzaboR, BuggeTH (2011) Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annual review of cell and developmental biology 27: 213–235.

16. ListK, HaudenschildCC, SzaboR, ChenW, WahlSM, et al. (2002) Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21: 3765–3779.

17. ListK, SzaboR, WertzPW, SegreJ, HaudenschildCC, et al. (2003) Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. The Journal of cell biology 163: 901–910.

18. ListK, KosaP, SzaboR, BeyAL, WangCB, et al. (2009) Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. The American journal of pathology 175: 1453–1463.

19. SzaboR, MolinoloA, ListK, BuggeTH (2007) Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene 26: 1546–1556.

20. SzaboR, HobsonJP, ChristophK, KosaP, ListK, et al. (2009) Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development 136: 2653–2663.

21. VuTK, HungDT, WheatonVI, CoughlinSR (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057–1068.

22. SohUJ, DoresMR, ChenB, TrejoJ (2010) Signal transduction by protease-activated receptors. British journal of pharmacology 160: 191–203.

23. TraynelisSF, TrejoJ (2007) Protease-activated receptor signaling: new roles and regulatory mechanisms. Current opinion in hematology 14: 230–235.

24. ConnollyAJ, IshiharaH, KahnML, FareseRVJr, CoughlinSR (1996) Role of the thrombin receptor in development and evidence for a second receptor. Nature 381: 516–519.

25. DamianoBP, CheungWM, SantulliRJ, Fung-LeungWP, NgoK, et al. (1999) Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. The Journal of pharmacology and experimental therapeutics 288: 671–678.

26. CamererE, BarkerA, DuongDN, GanesanR, KataokaH, et al. (2010) Local protease signaling contributes to neural tube closure in the mouse embryo. Developmental cell 18: 25–38.

27. FriisS, Uzzun SalesK, GodiksenS, PetersDE, LinCY, et al. (2013) A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation. J Biol Chem 288: 19028–19039.

28. TakeuchiT, HarrisJL, HuangW, YanKW, CoughlinSR, et al. (2000) Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275: 26333–26342.

29. SzaboR, Uzzun SalesK, KosaP, ShyloNA, GodiksenS, et al. (2012) Reduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation. PLoS genetics 8: e1002937.

30. Diez-RouxG, BanfiS, SultanM, GeffersL, AnandS, et al. (2011) A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol 9: e1000582.

31. CoppAJ (1995) Death before birth: clues from gene knockouts and mutations. Trends in genetics: TIG 11: 87–93.

32. CamererE, KataokaH, KahnM, LeaseK, CoughlinSR (2002) Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem 277: 16081–16087.

33. TallquistMD, SorianoP (2000) Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function. Genesis 26: 113–115.

34. DilworthMR, SibleyCP (2013) Review: Transport across the placenta of mice and women. Placenta 34 Suppl: S34–39.

35. CoanPM, AngioliniE, SandoviciI, BurtonGJ, ConstanciaM, et al. (2008) Adaptations in placental nutrient transfer capacity to meet fetal growth demands depend on placental size in mice. The Journal of physiology 586: 4567–4576.

36. Wright C, Sibley C.P. (2011) Placental Transfer in Health and Disease; Kay H, Nelson, D.M., Wang, Y., editor: Blackwell Publishing Ltd.

37. MiS, LeeX, LiX, VeldmanGM, FinnertyH, et al. (2000) Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 403: 785–789.

38. SchreiberJ, Riethmacher-SonnenbergE, RiethmacherD, TuerkEE, EnderichJ, et al. (2000) Placental failure in mice lacking the mammalian homolog of glial cells missing, GCMa. Mol Cell Biol 20: 2466–2474.

39. GluckmanPD, HansonMA, CooperC, ThornburgKL (2008) Effect of in utero and early-life conditions on adult health and disease. The New England journal of medicine 359: 61–73.

40. FanB, BrennanJ, GrantD, PealeF, RangellL, et al. (2007) Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth. Dev Biol 303: 222–230.

41. CenacN, CoelhoAM, NguyenC, ComptonS, Andrade-GordonP, et al. (2002) Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. The American journal of pathology 161: 1903–1915.

42. HachemJP, HoubenE, CrumrineD, ManMQ, SchurerN, et al. (2006) Serine protease signaling of epidermal permeability barrier homeostasis. The Journal of investigative dermatology 126: 2074–2086.

43. ChinAC, LeeWY, NusratA, VergnolleN, ParkosCA (2008) Neutrophil-mediated activation of epithelial protease-activated receptors-1 and -2 regulates barrier function and transepithelial migration. Journal of immunology 181: 5702–5710.

44. SendoT, SumimuraT, ItohY, GoromaruT, AkiK, et al. (2003) Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells. Cellular signalling 15: 773–781.

45. GuY, GroomeLJ, AlexanderJS, WangY (2012) PAR-2 triggers placenta-derived protease-induced altered VE-cadherin reorganization at endothelial junctions in preeclampsia. Placenta 33: 803–809.

46. FuruseM, HataM, FuruseK, YoshidaY, HaratakeA, et al. (2002) Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 156: 1099–1111.

47. BuzzaMS, Netzel-ArnettS, Shea-DonohueT, ZhaoA, LinCY, et al. (2010) Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci U S A 107: 4200–4205.

48. DeryO, CorveraCU, SteinhoffM, BunnettNW (1998) Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. The American journal of physiology 274: C1429–1452.

49. RamsayAJ, ReidJC, AdamsMN, SamaratungaH, DongY, et al. (2008) Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biological chemistry 389: 653–668.

50. GrimseyN, SotoAG, TrejoJ (2011) Regulation of protease-activated receptor signaling by post-translational modifications. IUBMB life 63: 403–411.

51. SzaboR, RasmussenAL, MoyerAB, KosaP, SchaferJM, et al. (2011) c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene 30: 2003–2016.

52. KimC, LeeHS, LeeD, LeeSD, ChoEG, et al. (2011) Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration. Blood 117: 1415–1424.

53. ChenM, ChenLM, LinCY, ChaiKX (2008) The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. Biochim Biophys Acta 1783: 896–903.

54. JinX, YagiM, AkiyamaN, HirosakiT, HigashiS, et al. (2006) Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 97: 1327–1334.

55. AhmedS, JinX, YagiM, YasudaC, SatoY, et al. (2006) Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). Febs J 273: 615–627.

56. BhattAS, Erdjument-BromageH, TempstP, CraikCS, MoasserMM (2005) Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 24: 5333–5343.

57. SuzukiM, KobayashiH, KanayamaN, SagaY, SuzukiM, et al. (2004) Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 279: 14899–14908.

58. KangJY, Dolled-FilhartM, OcalIT, SinghB, LinCY, et al. (2003) Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63: 1101–1105.

59. LeeSL, DicksonRB, LinCY (2000) Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275: 36720–36725.

60. UstachCV, HuangW, Conley-LaCombMK, LinCY, CheM, et al. (2010) A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 70: 9631–9640.

61. BergumC, ZorattiG, BoernerJ, ListK (2012) Strong expression association between matriptase and its substrate prostasin in breast cancer. J Cell Physiol 227: 1604–1609.

62. SalesKU, MasedunskasA, BeyAL, RasmussenAL, WeigertR, et al. (2010) Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nature genetics 42: 676–683.

63. SchmidlinF, AmadesiS, DabbaghK, LewisDE, KnottP, et al. (2002) Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 169: 5315–5321.